Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Emerging Infectious Diseases Année : 2018

Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission

Résumé

We conducted a multicenter, retrospective cohort study of hospitalized patients with serologically proven nephropathia epidemica (NE) living in Ardennes Department, France, during 2000-2014 to develop a bioclinical test predictive of severe disease. Among 205 patients, 45 (22.0%) had severe NE. We found the following factors predictive of severe NE: nephrotoxic drug exposure (p = 0.005, point value 10); visual disorders (p = 0.02, point value 8); microscopic or macroscopic hematuria (p = 0.04, point value 7); leukocyte count >10 × 109 cells/L (p = 0.01, point value 9); and thrombocytopenia <90 × 109/L (p = 0.003, point value 11). When point values for each factor were summed, we found a score of <10 identified low-risk patients (3.3% had severe disease), and a score >20 identified high-risk patients (45.3% had severe disease). If validated in future studies, this test could be used to stratify patients by severity in research studies and in clinical practice.
Fichier principal
Vignette du fichier
17-2160.pdf (1.39 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

pasteur-01834306 , version 1 (10-07-2018)

Licence

Paternité

Identifiants

Citer

Maxime Hentzien, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, et al.. Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission. Emerging Infectious Diseases, 2018, 24 (6), pp.1045 - 1054. ⟨10.3201/eid2406.172160⟩. ⟨pasteur-01834306⟩

Collections

PASTEUR
172 Consultations
171 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More